Literature DB >> 8339263

Mutations of the p53 gene do not occur in testis cancer.

H Q Peng1, D Hogg, D Malkin, D Bailey, B L Gallie, M Bulbul, M Jewett, J Buchanan, P E Goss.   

Abstract

To characterize the role of p53 in the development of testis cancer, we looked for mutations in the coding sequences of the p53 gene. DNA was obtained both from familial and sporadic testis cancer specimens, as well as from peripheral blood from members of a testis cancer kindred. Mutations in the p53 gene were screened using a combination of constant denaturant gel electrophoresis and single-strand conformational polymorphism analysis, 2 screening methods that can detect single base changes. Abnormalities detected by these methods were confirmed by sequencing of the corresponding cloned polymerase chain reaction products. All conserved regions of the p53 coding sequences were examined, encompassing all previously reported sites of mutations. No mutations were found in any of 22 germ cell cancers of the testis or in the germline DNA of 17 members of the testis cancer family. This is in striking contrast to most other human cancers, in which mutations of p53 are the most commonly described molecular event associated with tumorigenesis. We conclude that dysfunction of tumor suppressor gene or genes other than p53 may prove to play an important role in the development of germ cell cancers of the testis.

Entities:  

Mesh:

Year:  1993        PMID: 8339263

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

Review 1.  Demystified ... p53.

Authors:  S J Darnton
Journal:  Mol Pathol       Date:  1998-10

2.  Serine/threonine kinase 17A is a novel p53 target gene and modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells.

Authors:  Pingping Mao; Mary P Hever; Lynne M Niemaszyk; Jessica M Haghkerdar; Esty G Yanco; Damayanti Desai; Maroun J Beyrouthy; Joanna S Kerley-Hamilton; Sarah J Freemantle; Michael J Spinella
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

Review 3.  Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters.

Authors:  C Bokemeyer; M A Kuczyk; J Serth; J T Hartmann; H J Schmoll; U Jonas; L Kanz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  Molecular genetics of testicular germ cell tumors.

Authors:  Yuri Sheikine; Elizabeth Genega; Jonathan Melamed; Peng Lee; Victor E Reuter; Huihui Ye
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

Review 5.  Molecular biology of testicular germ cell tumors: current status.

Authors:  B Schmidt; R Ackermann; T Strohmeyer
Journal:  J Mol Med (Berl)       Date:  1995-07       Impact factor: 4.599

6.  p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors.

Authors:  Baozong Li; Qian Cheng; Zhenyu Li; Jiandong Chen
Journal:  Cell Cycle       Date:  2010-04-01       Impact factor: 4.534

7.  Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells.

Authors:  Caryl J Giuliano; Sarah J Freemantle; Michael J Spinella
Journal:  Curr Cancer Ther Rev       Date:  2006-08-01

8.  Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.

Authors:  L Diller; E Sexsmith; A Gottlieb; F P Li; D Malkin
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas.

Authors:  C R Boschman; S Stryker; J K Reddy; M S Rao
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

10.  NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas.

Authors:  Y Yu; F Xu; H Peng; X Fang; S Zhao; Y Li; B Cuevas; W L Kuo; J W Gray; M Siciliano; G B Mills; R C Bast
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.